AbbVie Inc. Reports Strong Q1 2026 Earnings with Growth in Immunology and Neuroscience

AbbVie Inc. (ABBV) exceeded earnings expectations in Q1 2026, driven by strong performance in immunology and neuroscience. The company raised its full-year adjusted EPS guidance to $14.08–$14.28, citing confidence in sustained demand for its core growth portfolio. Strategic investments in manufacturing and R&D were highlighted, along with long-term growth potential in new indications for Skyrizi.

By Moby Intelligence Wed, April 29, 2026 at 7:49 PM GMT+3 3 min read · Yahoo Finance · April 29, 2026, 16:49 UTC

Tickers: $ABBV

Topics: Earnings Beat Guidance Update Market Share Gains Product Performance Strategic Investments

Read the full article at Yahoo Finance

More World news

Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC